在已经接受每四周给药的先前生物制剂治疗失败的克罗恩病患者中，静脉注射乌司奴单抗再诱导治疗是有效的。
Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing.
机构信息
Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.
Robarts Clinical Trials, London, Ontario, Canada.
出版信息
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1497-1498.e1. doi: 10.1016/j.cgh.2020.07.064. Epub 2020 Aug 4.
Ustekinumab (UST) targets the common subunit (p40) of interleukins-12/23, approved for intravenous (IV) induction of remission in moderate-to-severe Crohn's disease (CD), followed by subcutaneous (SC) doses for maintenance of remission. The role of IV reinduction of UST in patients already on every-4-week (Q4) maintenance with partial response or loss of response (LOR) is unclear. The aim was to assess response and remission rates for UST IV reinduction in patients with CD with partial response or LOR who already were on Q4 SC dosing and had failed prior biological therapies.
乌司奴单抗（UST）靶向白细胞介素-12/23 的共同亚单位（p40），获批用于中重度克罗恩病（CD）的静脉（IV）诱导缓解，随后用皮下（SC）剂量维持缓解。对于已经接受每 4 周（Q4）维持治疗且部分缓解或失去缓解（LOR）的患者，乌司奴单抗 IV 再诱导的作用尚不清楚。本研究旨在评估对已接受 Q4 SC 剂量且先前生物治疗失败的部分缓解或 LOR 的 CD 患者进行 UST IV 再诱导的缓解和缓解率。
Zotero 插件